Jerome B Zeldis

This inventor holds 63 USPTO granted patents and 25 published patent applications, plus 7 CIPO patents and 7 EPO patents, primarily in Cancer Treatment (CPC class A61K). Top assignees: Celgene Corporation, Celegene Corporation, Therakos, Inc.. Active years: 1999-2022.

USPTO Granted Patents = 63 (Patent Applications = 25)

% Patents Active = 60.3

CIPO Patents = 7 (Patent Applications = 8)

EPO Patents = 7 (Patent Applications = 16)

Average Co-Inventor Count = 1.1

ph-index = 20

Forward Citations = 1,711(Granted Patents)

Forward Citations (Not Self Cited) = 1,426(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Princetone, NJ (US) (2007 - 2008)
Princeton, NJ (US) (1999 - 2022)

Company Filing History:

Signal Pharmaceuticals, Inc.

patents

7. 1 out of 3,690

The United States of America, as Represented by the Secretary, Department of Health and Human Services

patents

where one patent can have more than one assignee

Years Active: 1999-2022

Loading Chart...

Areas of Expertise:

Multiple Myeloma

Myelodysplastic Syndromes

Immunomodulatory Compounds

PDE4 Modulators

Stem Cell Transplantation

Biomarkers

Lymphoma

Leukemias

Combination Therapy

Proteasome Inhibitor

Acute Myelogenous Leukemia

Kaposi's Sarcoma

63 patents (USPTO):Sort by Forward CitationsExplore Patents

1. RE48890 - Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation (2022-01-10),

2. 11116782 - Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine (2021-09-14),

3. 10682336 - PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS) (2020-06-16),

4. 10206914 - Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation (2019-02-19),

5. 10001483 - Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers (2018-06-19),

6. 9925207 - Methods of treating myelodysplastic syndromes using lenalidomide (2018-03-27),

7. 9662321 - Methods for treating newly diagnosed multiple myeloma with 3-(4-amino-1-OXO-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with second active agents (2017-05-30),

8. 9498472 - Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias (2016-11-22),

9. 9408831 - Methods for treating respiratory viral infection (2016-08-09),

10. 9393238 - Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent (2016-07-19),

11. 9283215 - Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione in combination with antibodies (2016-03-15),

12. 9155730 - Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent (2015-10-13),

13. 9101622 - Methods for treating newly diagnosed multiple myeloma 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with dexamethasone (2015-08-11),

14. 9101621 - Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation (2015-08-11),

15. 9056120 - Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine (2015-06-16),

Title: Jerome B Zeldis: Pioneering Innovations in Biotechnology

Introduction:

Jerome B Zeldis, a prominent inventor, continues to shape the field of biotechnology with a relentless passion for innovation and a dedicated focus on enhancing global healthcare. With a track record of 63 patents to his name, Zeldis has become a guiding light for aspiring inventors and researchers worldwide.

Latest Patents:

Zeldis' latest patents showcase his commitment to advancing treatments for diseases like multiple myeloma and myelodysplastic syndromes. His innovative methods involve the administration of immunomodulatory compounds in combination with other active ingredients to effectively treat and manage these conditions. These patents also focus on reducing adverse side effects associated with traditional cancer therapies, offering new hope for patients.

Career Highlights:

Having worked in esteemed companies like Celgene Corporation and Therakos, Inc., Zeldis has been at the forefront of cutting-edge research and development in the biotechnology industry. His contributions have not only enhanced the quality of patient care but have also set new standards for innovation in the field.

Collaborations:

Throughout his illustrious career, Zeldis has collaborated with esteemed colleagues such as Andrew L Zeitlin and Maghsoud M Dariani. Together, they have pioneered groundbreaking research initiatives and have played a significant role in revolutionizing the treatment landscape for various medical conditions.

Conclusion:

Jerome B Zeldis' relentless pursuit of innovation and his unwavering dedication to improving global healthcare make him a true visionary in the field of biotechnology. His groundbreaking patents and collaborations serve as a testament to his impact on the industry, inspiring generations of inventors and researchers to follow in his footsteps.